Less than 30% of drugs in Nigeria made locally

15 July 2013

Last week, the Director General, of Nigeria’s National Agency for Foods, Drugs Administration and Control, NAFDAC, Paul Orhii, said less than 30 percent of essential medicines used in Nigeria was produced domestically, reports the local newspaper Vanguard. Dr Orhii said this when he received a delegation of Sierra Leone food and drugs regulators in Abuja.

He said: "One of the factors that encourage fake and substandard drugs in Nigeria is that we have low manufacturing capacity. What I did when I came in was to encourage our local manufacturers to increase production and also to upgrade facilities to meet international standards and most of them responded."

However, he pointed out that a few of the pharmaceutical companies in the country might obtain World Health Organization pre-qualification before the end of this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics